FDA Warns of Ketoacidosis, UTIs With SGLT2 Inhibitors

Manufacturers of sodium-glucose cotransporter-2 inhibitors are being required to add label warnings about the risks of ketoacidosis and urinary tract infections associated with their use.
Source: AAFP News - Category: Primary Care Source Type: news